Homologous recombination pathway alterations in basal-like breast cancer
-
By
-
Simon Aho
-
Boris Guyot
-
Véronique Maguer-Satta
-
June 18, 2026
-
Clinical Scorecard: Alterations in the Homologous Recombination Pathway in Basal-Like Breast Carcinoma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with basal-like breast cancer, particularly those with triple-negative phenotype, which is a defining characteristic. |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor for genomic instability and treatment response in HRD-positive patients, focusing on specific markers such as chromosomal aberrations.
Risks
Patient & Prescribing Data
Patients with basal-like breast cancer, particularly those with triple-negative characteristics.
HRD assessment may help identify patients more likely to benefit from specific therapies.
Clinical Best Practices
- Integrate HRD assessment into routine clinical practice to guide treatment decisions.
Related Resources & Content
